{"url_path":"/sec/kalv/8-k/2026-06-11/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-11","source_url":"https://www.sec.gov/Archives/edgar/data/1348911/0001140361-26-024949-index.html","accession_number":"0001140361-26-024949","cik":"0001348911","ticker":"KALV","issuer_name":"KalVista Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1348911/0001140361-26-024949-index.html","primary_entity_key":"0001348911","primary_entity_name":"KalVista Pharmaceuticals, Inc."},"word_count":289,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits\n\nExhibit\n\nNumber\n\nDescription\n\n \n\n \n\n[2.1*](https://www.sec.gov/Archives/edgar/data/1348911/000114036126017656/ef20071670_ex2-1.htm)\n\nAgreement and Plan of Merger, dated as of April 29, 2026, by and among KalVista Pharmaceuticals, Inc., Chiesi Farmaceutici S.p.A., Skyline Merger Sub,\nInc. and KalVista Pharmaceuticals Limited (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed with the SEC on April 29, 2026).\n\n[3.1](ny20075902x2_ex3-1.htm)\n\nAmended and Restated Certificate of Incorporation of KalVista Pharmaceuticals, Inc., dated June 11, 2026.\n\n[3.2](ny20075902x2_ex3-2.htm)\n\nAmended and Restated Bylaws of KalVista Pharmaceuticals, Inc., dated June 11, 2026.\n\n[4.1](https://www.sec.gov/Archives/edgar/data/1348911/000119312525274442/kalv-ex4_1.htm)\n\nIndenture, dated as of September 29, 2025, between KalVista Pharmaceuticals, Inc. and U.S. Bank Trust Company, National Association, as trustee\n(incorporated by reference to Exhibit 4.1 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on November 10, 2025).\n\n[4.2](ny20075902x2_ex4-2.htm)\n\nFirst Supplemental Indenture, dated as of June 11, 2026, between KalVista Pharmaceuticals, Inc. and U.S. Bank Trust Company, National Association, as\ntrustee.\n\n[99.1](ny20075902x2_ex99-1.htm)\n\nJoint Press Release, dated June 11, 2026, issued by KalVista Pharmaceuticals, Inc. and Chiesi Farmaceutici S.p.A.\n\n \n\n \n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n*\n\nSchedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplemental copies of any of the\nomitted schedules upon request by the SEC; provided, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any schedules so furnished.\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned\nhereunto duly authorized.\n\n \n\nKALVISTA PHARMACEUTICALS, INC.\n\n \n\n \n\n \n\nDate: June 11, 2026\n\nBy:\n\n/s/ John Hess\n\n \n\nName:\n\nJohn Hess\n\n \n\nTitle:\n\nChairman of the Board; President; General Manager"}